Canada’s Intellectual Property Firm

CADTH reports on integration of CDIAC functions into pCODR process

On June 12, 2019, the Canadian Agency for Drugs and Technologies in Health (CADTH) reported changes (effective July 1, 2019) to transition Cancer Drug Implementation Advisory Committee (CDIAC) functions to the CADTH pan-Canadian Oncology Drug Review (pCODR) review process. The purpose of the changes is to:

  • “enhance the transparency of the pan-Canadian cancer drug review process”;
  • “allow for greater stakeholder input into the development of a provisional algorithm for each new cancer drug or indication to indicate how the new therapy could be used compared to existing funded treatments; and to indicate the impact on the sequence of use for other existing funded therapies to better support jurisdictional decision-making for drug reimbursement”; and
  • “streamline and reduce the duplication of administrative processes”.

The reported changes follow a period (beginning March 2019) of consultation with stakeholders.